Pro Medicus initiated with a Sell at CLSA

CLSA analyst Andrew Paine initiated coverage of Pro Medicus with a Sell rating and A$54.25 price target. The stock is fully priced at these levels, especially against the backdrop of ongoing macro uncertainty, Paine tells investors in a research note.